MedTrace Logo

BXCL701 Phase 1 R/R Acute Myeloid Leukemia or Myelodysplastic Syndrome

NCT05703542 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2025-07-18

No results posted yet for this study

Summary

The goal of this research study is to find the safest and most effective dose of the study drug, BXCL701, for the treatment of Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS).

The names of the study drugs involved in this study are/is:

* BXCL701

Conditions

Interventions

DRUG

BXCL701

Tablet, taken Orally

Sponsors & Collaborators

  • Eric Stephen Winer, MD

    lead OTHER

Principal Investigators

  • Eric S Winter, MD · Dana-Farber Cancer Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-02
Primary Completion
2026-03-17
Completion
2026-07-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05703542 on ClinicalTrials.gov